Last $0.14 USD
Change Today -0.02 / -12.12%
Volume 1.1K
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

progen pharmaceuticals ltd (PGLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/14 - $1.86
52 Week Low
02/27/15 - $0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

progen pharmaceuticals ltd (PGLA) Related Businessweek News

No Related Businessweek News Found

progen pharmaceuticals ltd (PGLA) Details

Progen Pharmaceuticals Limited, a biotechnology company, discovers, researches, and develops biopharmaceutical therapeutics for the treatment of human diseases in Australia and the United States. It focuses on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The company’s products in research and development stage include PG545, an anti-cancer compound in preclinical development; and PI-88 melanoma program that is in Phase III clinical trial in post-resection liver cancer. It also provides contract services related to the process development, manufacture, and quality assurance of biological products. Progen Pharmaceuticals Limited is based in Darra, Australia.

progen pharmaceuticals ltd (PGLA) Top Compensated Officers

General Manager of Finance
Total Annual Compensation: A$104.1K
Chief Executive Officer of Pharmasynth Pty Lt...
Total Annual Compensation: A$146.3K
Director of Legal & Business Development
Total Annual Compensation: A$167.6K
Non-Executive Director, Chairman of Audit Com...
Total Annual Compensation: A$177.8K
Director of Drug Development
Total Annual Compensation: A$154.3K
Compensation as of Fiscal Year 2014.

progen pharmaceuticals ltd (PGLA) Key Developments

Progen Pharmaceuticals Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Progen Pharmaceuticals Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported revenue of AUD 2,549,909 against AUD 1,354,906 a year ago. Loss before income tax expense was AUD 2,045,104 against AUD 1,962,310 a year ago. Net loss for the period was AUD 2,045,104 or 3.70 cents per basic and diluted share against AUD 1,962,310 or 3.55 cents per basic and diluted share a year ago. Net cash flows used in operating activities was AUD 1,755,002 against AUD 1,849,751 a year ago. Purchase of plant and equipment was AUD 295,756 against AUD 263,964 a year ago.

Progen Pharmaceuticals Provides Clinical Trial Update on PI-88

Progen Pharmaceuticals Ltd. provided the information on the PI-88 PATRON clinical trial received from its licensee, Medigen Biotechnology Corporation (‘Medigen’). On 26 January 2015, the Medigen Board of Directors resolved to bring forward the analysis of PI-88 Phase III PATRON clinical trial data, and will inform the Taiwan Food and Drug Administration (“TFDA”) of this decision. As of 26 January 2015, all 520 patients in the PATRON trial have completed treatment with either PI-88 or the placebo. The PATRON clinical trial is a Phase III randomised, placebo-controlled trial being conducted in Taiwan, South Korea, China and Hong Kong to confirm the safety and efficacy of PI-88 in the adjuvant treatment of hepatocellular carcinoma after surgical resection. Pursuant to the clinical trial design, patients were to be treated for 12 months with either PI-88 or the placebo and receive follow-up for two years. Following this decision by the Medigen Board, other than patients receiving antiviral therapy, the patients will not receive any further follow-up beyond a final study visit to be conducted within the next 28 days. Medigen will now execute a study conclusion plan for the PATRON trial with the clinical trial sites and investigators. After the collection of the clinical data, a comprehensive statistical analysis will be carried out and a final clinical study report prepared. The final clinical study report will be submitted to TFDA after the completion of data collection and analysis. Medigen will make a decision on the next phase of PI-88 based on the final result of data analysis and discussion with regulatory authorities.

Progen Pharmaceuticals Ltd Completes Assessment of the Third Patient Cohort in its PG545 Phase 1 Clinical Trial

Progen Pharmaceuticals Limited announced that it has completed assessment of the third patient cohort in its PG545 Phase 1 clinical trial. Progen together with an independent medical monitor and the coordinating investigators have reviewed the safety data from this cohort and have agreed to progress to the next dose level of PG545. Each patient in the third cohort received once-weekly 100 mg doses of PG545. No dose limiting toxicities were reported from the group following at least four weeks of treatment. Accordingly, the recruitment of the fourth cohort of three patients has commenced. Each of the patients in the fourth group will receive 150 mg doses of PG545 at once-weekly intervals. The current study is entitled an open-label, multi-centre Phase I study of the safety and tolerability of IV infused PG545 in patients with advanced solid tumours'. The study is expected to enrol approximately 25 advanced cancer patients. The primary objective of the study is the determination of the maximum tolerated dose (MTD) as defined by significant dose limiting toxicity (DLT). The secondary objectives are: Assessment of the safety and tolerability of PG545 following multiple doses in subjects with advanced solid malignancies; To estimate pharmacokinetic parameters of PG545 and explore pharmacokinetic/pharmacodynamic relationships; and To document any antitumour activity observed with PG545.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGLA:US $0.14 USD -0.02

PGLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PGLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation PGLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.2x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGEN PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at